Back to search results

ApricityCare Program for Managing Treatment Side Effects in Metastatic Cancer

This study is looking at a program called ApricityCare to help people with metastatic cancer (cancer that has spread to other parts of the body) manage side effects from their cancer treatment. The goal is to see if using ApricityCare can help reduce how often people have to stop their treatment because of side effects. Researchers also want to understand how easy ApricityCare is for patients to use and how well it helps them report symptoms. You might be able to join if you are 18 or older, have a confirmed cancer diagnosis, and will be starting systemic therapy. The study aims to enroll about 425 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll about 425 participants.
What's involved
Participants will be asked to take part in the ApricityCare program because they have metastatic cancer and will be starting systemic therapy.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06693687

A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

Recruiting
NAAges 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~425 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:Metastatic Cancer

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events
Measured over Through study completion; an average of 1 year.

Conditions

Metastatic Cancer

Explore related trials

Bladder CarcinomaKidney CarcinomaProstate CarcinomaSolid Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Who to contact

Bilal A Siddiqui, MD
[email protected]
(713) 563-4600
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years of age or older
Confirmed diagnosis of cancer
Part 1 (Run-in Phase): Only patients with prostate, kidney, and/or bladder cancer will be enrolled with either localized or metastatic disease.
Part 2 (Expansion Phase): Metastatic patients will be enrolled. Note, evaluable metastatic patients from Ppart 1 will be counted in Cohort A as described in section 8.4.
Planned to receive systemic anti-cancer therapy
Ability to understand and the willingness to sign a written informed consent document
Ability to speak, read, and understand one of the following languages: English, Spanish, Mandarin and Cantonese Chinese
Ownership of a smartphone and willingness to use it as outlined by the protocol and described in the ICF

What this trial measures

  • Safety and Adverse EventsThrough study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03